Brendan Kelly, Ph.D.
InvestorPrincipal at Lightstone Ventures
About
Brendan Kelly combines medicinal chemistry and computational drug discovery work at Trinity College Dublin, University of Toronto and Stanford with founding A2a Pharmaceuticals and peer‑reviewed publications to assess biotech platforms.
Invests in
BiotechHealthtechMedical Devices
Colleagues at Lightstone Ventures
Brendan Kelly
Principal at Lightstone Ventures
Caroline Gaynor
Partner at Lightstone Ventures
Christina Isacson
Partner at Lightstone Ventures
Christina Isacson, Ph.D.
Partner at Lightstone Ventures
Doug Treco
Advisor at Lightstone Ventures
Doug Treco, Ph.D.
Advisor at Lightstone Ventures
Frank D. Lee
Advisor at Lightstone Ventures
H. Martin Seidel
Advisor at Lightstone Ventures
Frequently asked questions
- Who is Brendan Kelly, Ph.D.?
- Brendan Kelly combines medicinal chemistry and computational drug discovery work at Trinity College Dublin, University of Toronto and Stanford with founding A2a Pharmaceuticals and peer‑reviewed publications to assess biotech platforms.
- Where does Brendan Kelly, Ph.D. work?
- Brendan Kelly, Ph.D. is Principal at Lightstone Ventures.
- What does Brendan Kelly, Ph.D. invest in?
- Brendan Kelly, Ph.D. invests in Biotech, Healthtech, Medical Devices.